- Report
- April 2025
- 175 Pages
Global
From €3965EUR$4,490USD£3,440GBP
- Report
- September 2025
- 179 Pages
Global
From €5165EUR$5,850USD£4,482GBP
- Report
- May 2025
- 106 Pages
Global
From €4194EUR$4,750USD£3,640GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3179EUR$3,600USD£2,758GBP
- Report
- October 2022
- 177 Pages
From €3046EUR$3,450USD£2,643GBP
- Report
- October 2022
- 174 Pages
North America
From €3046EUR$3,450USD£2,643GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €3046EUR$3,450USD£2,643GBP
- Report
- October 2022
- 202 Pages
Europe
From €3046EUR$3,450USD£2,643GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3046EUR$3,450USD£2,643GBP
- Report
- July 2022
- 255 Pages
Global
From €3929EUR$4,450USD£3,410GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 100 Pages
Global
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 80 Pages
Europe
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4194EUR$4,750USD£3,640GBP
- Report
- February 2024
- 70 Pages
India
From €4194EUR$4,750USD£3,640GBP

Tresiba is a brand of long-acting insulin used to treat diabetes, a chronic endocrine and metabolic disorder. It is a basal insulin, meaning it is taken once or twice daily to provide a steady, low level of insulin throughout the day. It is used to control blood sugar levels in adults and children with type 1 and type 2 diabetes. It is also used to treat diabetic ketoacidosis, a serious complication of diabetes. Tresiba is available in both a pen and a vial form, and is taken in combination with other diabetes medications.
The Tresiba market is a competitive one, with several companies offering similar products. These include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Each company offers a range of long-acting insulin products, including Tresiba, to meet the needs of people with diabetes. Show Less Read more